FT
SUPN icon

Fiduciary Trust’s Supernus Pharmaceuticals SUPN Stock Holding History

Fiduciary Trust’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$683K Sell
14,695
-19
-0.1% -$913 0.01% 511
2026
Q1 		$761K Hold
14,714
– – 0.01% 472
2025
Q4 		$731K Buy
14,714
+661
+5% +$32.1K 0.01% 478
2025
Q3 		$672K Sell
14,053
-1,705
-11% -$68.7K 0.01% 494
2025
Q2 		$497K Buy
15,758
+5
+0% +$160 0.01% 535
2025
Q1 		$516K Buy
+15,753
New +$558K 0.01% 515

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Fiduciary Trust's SUPN Position: Q2 2026 in Review

Fiduciary Trust reduced its Supernus Pharmaceuticals (SUPN) stake by 0.13% in Q2 2026, selling an estimated $913 and leaving 14,695 shares worth $683K. The position accounts for 0.01% of the portfolio, ranked #511.

Fiduciary Trust first reported a position in SUPN in Q1 2025 and has held it in 6 quarters since. The position peaked at $761K in Q1 2026. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Fiduciary Trust held 14,695 shares of Supernus Pharmaceuticals worth $683K as of Q2 2026.
  • Fiduciary Trust sold 19 Supernus Pharmaceuticals shares in Q2 2026, an estimated $913.
  • Supernus Pharmaceuticals made up 0.01% of Fiduciary Trust's portfolio in Q2 2026, its #511 holding.
  • Fiduciary Trust first reported a position in Supernus Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Fiduciary Trust's Supernus Pharmaceuticals position peaked at $761K in Q1 2026.
  • 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.